从藤黄中分离出的gamma-mangostin通过下调GSK3β/β-catenin/cdk6癌症茎途径来抑制结肠癌的发生和干性。
摘要来源：摘要来源：
phytomedicine。 2022年1月; 95：153797。 EPUB 2021 10月21日。PMID： 34802869 34802869 Yan-Jiun Huang，Ntlotlang Mokgautsi，Bashir Lawal，Tse-Hung Huang
文章隶属关系：Alexander th Wu
摘要：
假设： gamma-mangostin（gmg），从甘奇尼亚分离出的Mangostana被评估了其从甘氏岩中分离出来 resistance and CSC generation.
METHODS: Bioinformatics analysis, in silico molecular docking, in vitro assays, including cell viability tests, colony- and tumor sphere-formation assays, transwell migration assays, ELISA, SDS-PAGE, Western blotting, miR expression, qPCR, and flow cytometry, as well as in vivo mouse xenograft models were used to evaluate the antitumor effects of gMG.
RESULTS: Bioinformatics analyses indicated that GSK3β/CDK6/β-catenin mRNA signature was significantly higher in colon cancer patients.其他算法预测了更高的miR-26b水平与CRC患者以及GSK3β和CDK6作为miR-26b-5p的靶标有显着较高的生存率有关。为了在体外验证这些发现，我们表明CAF培养的CRC细胞表达了GSK3β，β-catenin，cdk6和NF-κB的表达增加。在治疗上，我们证明GMG治疗抑制了与GSK3β相关的信号通路，而同时增加了miR-26b-5p水平。 Using a xenograft mouse model of CAFs cocultured HCT116 tumorspheres, we showed that gMG treatment reduced tumor growth and overcame CAF-induced 5-fluorouracil resistance.
CONCLUSIONS: Pharmacological intervention with gMG suppressed CRC carcinogenesis and stemness via下调GSK3/β-catenin/cdk6并上调miR-26b-5p肿瘤抑制剂。因此，GMG代表了一种潜在的新CRC治疗剂，并需要进一步研究。